株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

ヒトインスリンの世界市場 - 業界動向、シェア、規模、成長率、機会、予測

Human Insulin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025

発行 IMARC Services Private Limited 商品コード 933950
出版日 ページ情報 英文 108 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.54円で換算しております。
ヒトインスリンの世界市場 - 業界動向、シェア、規模、成長率、機会、予測 Human Insulin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025
出版日: 2020年04月16日 ページ情報: 英文 108 Pages
概要

世界のヒトインスリン市場は、2019年の348億米ドルから、2025年までに583億米ドルまで拡大し、2020年~2025年のCAGRで約9%の成長が予測されています。ヒトインスリン (HI) は、製薬用途で合成される、合成インスリンの一種です。

当レポートでは、世界のヒトインスリン市場について調査分析し、市場概要、市場規模と予測、市場内訳、競合情勢などについて、体系的な情報を提供しています。

目次

第1章 序文

第2章 範囲と調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界のヒトインスリン市場

  • 市場概要
  • 市場実績

第6章 市場の内訳:製品タイプ別

  • 薬剤
  • デリバリーデバイス

第7章 市場の内訳:流通経路別

  • 小売薬局
  • 病院薬局
  • オンライン
  • その他

第8章 市場の内訳:疾患タイプ別

  • 1型糖尿病
  • 2型糖尿病

第9章 市場の内訳:地域別

  • 北米
  • アジア太平洋地域
  • 欧州
  • ラテンアメリカ
  • 中東・アフリカ

第10章 SWOT分析

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

第13章 価格指標

第14章 競合情勢

図表

List of Figures

  • Figure 1: Global: Human Insulin Market: Major Drivers and Challenges
  • Figure 2: Global: Human Insulin Market: Sales Value (in Billion US$), 2014-2019
  • Figure 3: Global: Human Insulin Market: Breakup by Product Type (in %), 2019
  • Figure 4: Global: Human Insulin Drug Market: Breakup by Type (in %), 2019
  • Figure 5: Global: Human Insulin Delivery Device Market: Breakup by Device Type (in %), 2019
  • Figure 6: Global: Human Insulin Market: Breakup by Distribution Channel (in %), 2019
  • Figure 7: Global: Human Insulin Market: Breakup by Disease Type (in %), 2019
  • Figure 8: Global: Human Insulin Market: Breakup by Region (in %), 2019
  • Figure 9: Global: Human Insulin Market Forecast: Sales Value (in Billion US$), 2020-2025
  • Figure 10: Global: Human Insulin (Drugs) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 11: Global: Human Insulin Drugs (Analogs and Biosimilars) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 12: Global: Human Insulin Drugs (Analogs and Biosimilars- Rapid Acting) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 13: Global: Human Insulin Drugs (Analogs and Biosimilars- Rapid Acting) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 14: Global: Human Insulin Drugs (Analogs and Biosimilars- Long Acting) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 15: Global: Human Insulin Drugs (Analogs and Biosimilars- Long Acting) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 16: Global: Human Insulin Drugs (Analogs and Biosimilars- Premixed Acting) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 17: Global: Human Insulin Drugs (Analogs and Biosimilars- Premixed Acting) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 18: Global: Human Insulin Drugs (Analogs and Biosimilars) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 19: Global: Human Insulin Drugs (Biologics) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 20: Global: Human Insulin Drugs (Biologics - Short Acting) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 21: Global: Human Insulin Drugs (Biologics - Short Acting) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 22: Global: Human Insulin Drugs (Biologics - Intermediate Acting) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 23: Global: Human Insulin Drugs (Biologics - Intermediate Acting) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 24: Global: Human Insulin Drugs (Biologics - Premixed) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 25: Global: Human Insulin Drugs (Biologics - Premixed) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 26: Global: Human Insulin Drugs (Biologics) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 27: Global: Human Insulin (Drugs) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 28: Global: Human Insulin (Delivery Devices) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 29: Global: Human Insulin Delivery Devices (Pens) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 30: Global: Human Insulin Delivery Devices (Pens) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 31: Global: Human Insulin Delivery Devices (Pen Needles) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 32: Global: Human Insulin Delivery Devices (Pen Needles) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 33: Global: Human Insulin Delivery Devices (Syringes) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 34: Global: Human Insulin Delivery Devices (Syringes) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 35: Global: Human Insulin Delivery Devices (Others) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 36: Global: Human Insulin Delivery Devices (Others) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 37: Global: Human Insulin (Delivery Devices) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 38: Global: Human Insulin Market: Sales through Retail Pharmacies (in Million US$), 2014 & 2019
  • Figure 39: Global: Human Insulin Market Forecast: Sales through Retail Pharmacies (in Million US$), 2020-2025
  • Figure 40: Global: Human Insulin Market: Sales through Hospital Pharmacies (in Million US$), 2014 & 2019
  • Figure 41: Global: Human Insulin Market Forecast: Sales through Hospital Pharmacies (in Million US$), 2020-2025
  • Figure 42: Global: Human Insulin Market: Sales through Online Retail Stores (in Million US$), 2014 & 2019
  • Figure 43: Global: Human Insulin Market Forecast: Sales through Online Retail Stores (in Million US$), 2020-2025
  • Figure 44: Global: Human Insulin Market: Sales through Other Distribution Channels (in Million US$), 2014 & 2019
  • Figure 45: Global: Human Insulin Market Forecast: Sales through Other Distribution Channels (in Million US$), 2020-2025
  • Figure 46: Global: Human Insulin (Type I Diabetes) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 47: Global: Human Insulin (Type I Diabetes) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 48: Global: Human Insulin (Type II Diabetes) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 49: Global: Human Insulin (Type II Diabetes) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 50: North America: Human Insulin Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 51: North America: Human Insulin Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 52: United States: Human Insulin Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 53: United States: Human Insulin Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 54: Canada: Human Insulin Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 55: Canada: Human Insulin Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 56: Asia Pacific: Human Insulin Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 57: Asia Pacific: Human Insulin Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 58: China: Human Insulin Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 59: China: Human Insulin Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 60: Japan: Human Insulin Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 61: Japan: Human Insulin Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 62: India: Human Insulin Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 63: India: Human Insulin Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 64: South Korea: Human Insulin Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 65: South Korea: Human Insulin Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 66: Australia: Human Insulin Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 67: Australia: Human Insulin Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 68: Indonesia: Human Insulin Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 69: Indonesia: Human Insulin Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 70: Others: Human Insulin Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 71: Others: Human Insulin Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 72: Europe: Human Insulin Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 73: Europe: Human Insulin Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 74: Germany: Human Insulin Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 75: Germany: Human Insulin Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 76: France: Human Insulin Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 77: France: Human Insulin Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 78: United Kingdom: Human Insulin Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 79: United Kingdom: Human Insulin Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 80: Italy: Human Insulin Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 81: Italy: Human Insulin Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 82: Spain: Human Insulin Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 83: Spain: Human Insulin Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 84: Russia: Human Insulin Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 85: Russia: Human Insulin Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 86: Others: Human Insulin Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 87: Others: Human Insulin Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 88: Latin America: Human Insulin Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 89: Latin America: Human Insulin Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 90: Brazil: Human Insulin Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 91: Brazil: Human Insulin Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 92: Mexico: Human Insulin Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 93: Mexico: Human Insulin Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 94: Others: Human Insulin Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 95: Others: Human Insulin Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 96: Middle East and Africa: Human Insulin Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 97: Middle East and Africa: Human Insulin Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 98: Global: Human Insulin Industry: SWOT Analysis
  • Figure 99: Global: Human Insulin Industry: Value Chain Analysis
  • Figure 100: Global: Human Insulin Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Human Insulin Market: Key Industry Highlights, 2019 and 2025
  • Table 2: Global: Human Insulin Market Forecast: Breakup by Product Type (in Million US$), 2020-2025
  • Table 3: Global: Human Insulin Drug Market Forecast: Breakup by Type (in Million US$), 2020-2025
  • Table 4: Global: Human Insulin Delivery Device Market Forecast: Breakup by Type (in Million US$), 2020-2025
  • Table 5: Global: Human Insulin Market Forecast: Breakup by Distribution Channel (in Million US$), 2020-2025
  • Table 6: Global: Human Insulin Market Forecast: Breakup by Disease Type (in Million US$), 2020-2025
  • Table 7: Global: Human Insulin Market Forecast: Breakup by Region (in Million US$), 2020-2025
  • Table 8: Global: Human Insulin Market: Competitive Structure
  • Table 9: Global: Human Insulin Market: Key Players
目次
Product Code: SR1019I29_Report

The global human insulin market reached a value of US$ 34.8 Billion in 2019. Human insulin (HI) is a form of synthetic insulin that is synthesized in laboratories for pharmaceutical use. It is bio-engineered by growing insulin proteins within E-coli bacteria (Escherichia coli) cells to mimic the properties of insulin naturally present in humans. The HI drugs are available in three kinds, namely rapid-acting, long-acting and premixed. They are used as a solution or suspension and are usually injected subcutaneously and aid in promoting the uptake of glucose from the blood into internal organs, such as fat cells, skeletal muscles and liver. They also inhibit hepatic glucose production, lipolysis and proteolysis and enhance protein synthesis in the body.

The increasing prevalence of obesity and diabetes across the globe is one of the key factors driving the growth of the market. Owing to sedentary lifestyles, growing geriatric population and unhealthy dietary habits, a greater number of individuals are suffering from chronic lifestyle diseases, thereby increasing the demand for insulin therapeutics. Furthermore, the growing requirement for biosimilar drugs, owing to their high efficiency and cost-effectiveness, is providing a boost to the market growth. Various technological advancements, such as the development of pen devices and safety pen needles, to administer HI in the body, are also creating a positive impact on the market growth. In comparison to standard needles, these safety pens ensure minimal injuries, discomfort and infections through bloodborne pathogen transmission. Other factors, including the increasing health consciousness among the masses and extensive research and development (R&D) in the field of biotechnology, are projected to drive the market further. Looking forward, IMARC Group expects the market to reach a value of US$ 58.3 Billion by 2025, exhibiting a CAGR of around 9% during 2020-2025.

Breakup by Product:

  • Drugs
  • Human Insulin Analogs and Biosimilars
  • Rapid Acting
  • Long Acting
  • Premixed
  • Human Insulin Biologics
  • Short Acting
  • Intermediate Acting
  • Premixed
  • Delivery Devices
  • Pens
  • Reusable Pens
  • Disposable Pens
  • Pen Needles
  • Standard Pen Needles
  • Safety Pen Needles
  • Syringes
  • Others

Breakup by Distribution Channel:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Retail Stores
  • Others

Breakup by Disease Type:

  • Type I Diabetes
  • Type II Diabetes

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

  • The competitive landscape of the industry has also been examined with some of the key players being B. Braun Melsungen AG, Becton Dickinson & Company, Biocon, Eli Lilly and Company, Julphar, Novo Nordisk, Pfizer, Sanofi, Sedico, Wockhardt, Ypsomed Holding, etc.

Key Questions Answered in This Report:

  • How has the global human insulin market performed so far and how will it perform in the coming years?
  • What are the key regional markets?
  • What is the breakup of the market based on the product type?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the delivery devices?
  • What is the breakup of the market based on the distribution channel?
  • What is the breakup of the market based on the disease type?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global human insulin market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Human Insulin Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Market Breakup by Types
      • 6.1.2.1 Human Insulin Analogs and Biosimilars
      • 6.1.2.1 Rapid Acting
      • 6.1.1.1 Market Trends
      • 6.1.1.2 Market Forecast
      • 6.1.2.2 Long Acting
      • 6.1.2.1 Market Trends
      • 6.1.2.2 Market Forecast
      • 6.1.2.3 Premixed
      • 6.1.3.1 Market Trends
      • 6.1.3.2 Market Forecast
      • 6.1.2.2 Human Insulin Biologics
      • 6.1.2.1 Short Acting
      • 6.2.1.1 Market Trends
      • 6.2.1.2 Market Forecast
      • 6.1.2.2 Intermediate Acting
      • 6.2.2.1 Market Trends
      • 6.2.2.1 Market Forecast
      • 6.1.2.3 Premixed
      • 6.2.3.1 Market Trends
      • 6.2.3.2 Market Forecast
    • 6.1.3 Market Forecast
  • 6.2 Delivery Devices
    • 6.2.1 Market Trends
    • 6.2.2 Major Types
      • 6.2.2.1 Pens
      • 6.2.2.1.1 Reusable Pens
      • 6.2.2.1.2 Disposable Pens
      • 6.2.2.2 Pen Needles
      • 6.2.2.2.1 Standard Pen Needles
      • 6.2.2.2.2 Safety Pen Needles
      • 6.2.2.3 Syringes
      • 6.2.2.4 Others
    • 6.2.3 Market Forecast

7 Market Breakup by Distribution Channel

  • 7.1 Retail Pharmacies
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Hospital Pharmacies
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Online
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Disease Type

  • 8.1 Type I Diabetes
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Type II Diabetes
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Indicators

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 B. Braun Melsungen AG
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 SWOT Analysis
    • 14.3.2 Becton Dickinson & Company
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Biocon
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Eli Lilly and Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Julphar
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Novo Nordisk
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Pfizer
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Sanofi
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Sedico
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Wockhardt
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
    • 14.3.11 Ypsomed Holding
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis